375 related articles for article (PubMed ID: 31438923)
1. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
2. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib: first global approval.
McCormack PL
Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
[TBL] [Abstract][Full Text] [Related]
6. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
7. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
8. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal JA
Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
Ikeda S; Ogura T; Kato T; Kenmotsu H; Agemi Y; Tokito T; Ito K; Isomoto K; Takiguchi Y; Yoneshima Y; Yokoyama T; Harada T; Tanzawa S; Kobayashi N; Iwasawa T; Misumi T; Okamoto H
Ann Am Thorac Soc; 2024 Apr; 21(4):635-643. PubMed ID: 38364204
[No Abstract] [Full Text] [Related]
14. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
16. [Nintedanib in the treatment of fibrosing interstital lung diseases].
Lewandowska K
Pol Merkur Lekarski; 2018 Mar; 44(261):139-141. PubMed ID: 29601564
[TBL] [Abstract][Full Text] [Related]
17. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
18. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
20. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
Valenzuela C; Torrisi SE; Kahn N; Quaresma M; Stowasser S; Kreuter M
Respir Res; 2020 Jan; 21(1):7. PubMed ID: 31906942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
